A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

As part of the ongoing probe in the case of bank fraud against M/s Sharon Bio Medicine Limited and others, Directorate of ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

Built on the Rapid Payments Programme (RPP) rails, PayShap has emerged as a key product driving digital transactions, fostering financial inclusion, and accelerating the country’s shift towards a ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...